Cardirest 50 & 100 50 mg, 100 mg Tablet
PDF Leaflet Revision Date: 11 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Control of sustained ventricular dysrhythmias and AV nodal reciprocating tachycardia.
Dosage (summary)
Starting 50 mg twice daily for supra-ventricular; 100 mg twice daily for ventricular dysrhythmias.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP2D6 inhibitors/inducers
- Class 1 anti-dysrhythmics
- Calcium channel blockers
Contraindications
- Hypersensitivity to flecainide
- Cardiac failure
- Recent myocardial infarction
- Structural heart disease
Common side effects
- Dizziness
- Visual disturbances
- Pro-dysrhythmic effects
Counselling Points
- Monitor for dizziness and visual disturbances.
- Avoid use with certain anti-dysrhythmics.
- Regular plasma level monitoring recommended.
Serious warnings
- Increased mortality risk in post-myocardial infarction patients
- Pro-dysrhythmic effects
- QT prolongation
Important Disclaimer
The Cardirest 50 & 100 50 mg, 100 mg Tablet professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
